Core Points - NurExone Biologic Inc. has been named a finalist in the Falling Walls Venture 2025, showcasing its potential in the field of science-based start-ups [1][2] - The company's lead product, ExoPTEN, aims to address central nervous system injuries, which impose significant personal and economic burdens [2][5] - NurExone will present its exosome-based regenerative therapy platform at the Falling Walls Science Summit in Berlin from November 6-9, 2025 [2][5] Company Overview - NurExone is a biotech company focused on developing regenerative exosome-based therapies for central nervous system injuries, with a strong emphasis on treating acute spinal cord and optic nerve injuries [5] - The company has received Orphan Drug Designation, facilitating its roadmap towards clinical trials in the U.S. and Europe [5] - NurExone has established Exo-Top Inc., a U.S. subsidiary, to support its North American growth strategy [5] Event Participation - As a finalist, NurExone will have access to exclusive networking events, connecting with investors, strategic partners, and global thought leaders [3] - The Falling Walls Venture serves as an international platform for science start-ups, with one winner being awarded the title 'Science Breakthrough of the Year' [4]